Neoplastic syndrome
MONDO:0021058A broad classification for disorders in which the development of neoplasms typically occur in association with a characteristic set of signs or symptoms. These disorders may be inherited or acquired.
Also known as: cancer-related syndrome, neoplastic syndrome, tumor syndrome, tumour syndrome
1282 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New daily pill aims to tame stubborn seizures in tuberous sclerosis
Disease control Not yet recruitingThis study tests an oral drug, AV078, in people aged 12 and older with tuberous sclerosis complex (TSC) whose seizures are not controlled by standard medications. Participants are randomly assigned to receive AV078 or a placebo for 12 weeks. The goal is to see if AV078 safely red…
Phase: PHASE2 • Sponsor: Aeovian Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could tailoring chemo by age make stem cell transplants safer for MDS patients?
Disease control Not yet recruitingThis study looks at two different chemotherapy combinations given before a half-matched stem cell transplant in adults with myelodysplastic syndrome (MDS). One regimen is designed for people aged 55 and older to reduce side effects, while the other is a standard stronger regimen …
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Three-Drug cocktail aims to tame transplant complications in blood cancer patients
Disease control Not yet recruitingThis trial investigates whether adding bortezomib and sitagliptin to standard post-transplant cyclophosphamide can prevent graft-versus-host disease (GvHD) in adults with blood cancers receiving a stem cell transplant. Participants receive the drug combination after transplant, w…
Phase: PHASE1, PHASE2 • Sponsor: Northwell Health • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a drug tame excess cortisol in a common hormone disorder?
Disease control Not yet recruitingThis study tests whether the drug metyrapone can safely lower cortisol levels in people with mild autonomous cortisol secretion (MACS), a condition where the adrenal glands produce too much cortisol. Participants will receive either metyrapone or a placebo for a short period, and…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New Antibody-Azacitidine combo aims to boost remission in High-Risk blood cancer
Disease control Not yet recruitingThis phase 2 trial tests whether adding bexmarilimab, an antibody that targets Clever-1, to standard azacitidine chemotherapy improves outcomes for adults with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS). Participants are randomly assigned to receive one of two…
Phase: PHASE2 • Sponsor: Faron Pharmaceuticals Ltd • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a simple antibiotic keep blood cancer patients out of the hospital?
Disease control Not yet recruitingThis study tests whether taking a daily antibiotic (levofloxacin) can safely reduce infections in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who are receiving chemotherapy as outpatients. The trial will randomly assign 75 participants to either lev…
Phase: PHASE2 • Sponsor: University of Manitoba • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New study aims to stop blood cancer relapse after transplant
Disease control Not yet recruitingThis study tests whether giving personalized maintenance therapy after a stem cell transplant can prevent cancer from coming back in people with certain blood cancers. About 450 adults with myeloid cancers who have signs of disease before transplant will be assigned to treatment …
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo aims to stop bleeding in bone marrow disease
Disease control Not yet recruitingThis phase 3 trial tests whether adding a platelet-boosting drug (rhTPO) to standard cyclosporine therapy can safely raise platelet counts in 78 adults with lower-risk myelodysplastic syndromes (MDS) who have very low platelets. The goal is to reduce bleeding and the need for pla…
Phase: PHASE3 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a stem cell shot before birth fix fanconi anemia?
Disease control Not yet recruitingThis early-phase trial tests whether giving healthy stem cells from the mother to a fetus diagnosed with Fanconi anemia can safely improve the baby's blood cell production. The treatment is a one-time injection into the fetus during pregnancy. The study will enroll 12 pregnant wo…
Phase: PHASE1, PHASE2 • Sponsor: Agnieszka Czechowicz • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to wipe out Hard-to-Treat leukemia and MDS
Disease control Not yet recruitingThis phase 2 trial tests whether adding olutasidenib to standard treatments helps people with IDH1-mutated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). For AML, the standard is a chemotherapy pill plus venetoclax; for higher-risk MDS, it's the chemotherapy pill…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment
Disease control Not yet recruitingThis trial tests whether adding the immunotherapy drugs cemiplimab (with or without fianlimab) to standard chemotherapy before chemoradiation can improve outcomes for people with advanced nasopharyngeal cancer. About 60 adults with non-metastatic, EBV-positive nasopharyngeal carc…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New study could change how Men's UTIs are treated
Disease control Not yet recruitingThis study tests whether a common antibiotic for women's UTIs, fosfomycin-trometamol, works well for men with urinary tract infections. Current treatments can have serious side effects and increase antibiotic resistance. The trial will enroll 138 men in primary care and monitor f…
Phase: PHASE3 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New combo therapy targets high-risk MDS in early trial
Disease control Not yet recruitingThis study tests a new two-drug combination (pacritinib plus azacitidine) for people with moderate to very high risk myelodysplastic syndrome (MDS), a bone marrow disorder. The first part finds the safest dose of pacritinib, and the second part checks how well the combination wor…
Phase: PHASE1, PHASE2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail aims to boost transplant success in tough leukemias
Disease control Not yet recruitingThis phase 2 trial tests whether adding two drugs (SHR2554 and azacitidine) to standard chemotherapy before a stem cell transplant can help people with high-risk or relapsed/refractory acute leukemia or myelodysplastic syndromes. About 180 participants aged 15-60 will be randomly…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo therapy aims to outsmart leukemia with less poison
Disease control Not yet recruitingThis phase 2 trial is testing a new way to treat adults newly diagnosed with a specific type of acute lymphoblastic leukemia (Ph-negative B-ALL). Instead of standard high-dose chemotherapy, patients receive a mix of low-dose chemo plus several targeted drugs (inotuzumab ozogamici…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Automated radiation could make stem cell transplants safer for blood cancer patients
Disease control Not yet recruitingThis trial tests a new automated radiation method that precisely targets bone marrow and lymph nodes before a stem cell transplant. The goal is to kill cancer cells while reducing damage to healthy tissues. Participants have high-risk myeloid cancers like acute myeloid leukemia o…
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug cocktail targets deadliest blood cancers
Disease control Not yet recruitingThis trial investigates whether adding selinisole to standard chemotherapy drugs (azacitidine and venetoclax) can improve outcomes for people with newly diagnosed, high-risk myeloid tumors that have a TP53 mutation. These tumors are aggressive and hard to treat. The study will me…
Phase: NA • Sponsor: Bing Han • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could a cancer drug boost social abilities in rare genetic condition?
Disease control Not yet recruitingThis study tests whether everolimus, a drug already approved for other conditions, can safely improve social abilities in people with PTEN Hamartoma Tumor Syndrome (PHTS). About 60 adults and children with PHTS and social difficulties will take either everolimus or a placebo for …
Phase: PHASE2, PHASE3 • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Promising new combo targets tough head and neck cancer
Disease control Not yet recruitingThis phase 2 trial tests a combination of two drugs—becotatug vedotin (a targeted therapy) and pucotenlimab (an immunotherapy)—as a first treatment for advanced head and neck squamous cell carcinoma. It is for patients whose cancer has returned or spread and who cannot tolerate p…
Phase: PHASE2 • Sponsor: Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug cocktail targets tough leukemia
Disease control Not yet recruitingThis early-stage trial tests a new drug called LP-118 alongside standard treatments for adults newly diagnosed with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). The study will enroll 26 people to find the safest dose and see if the combination helps control the d…
Phase: PHASE1 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New oral drug chidamide tested for Hard-to-Treat bone marrow disorder
Disease control Not yet recruitingThis phase 2 trial tests the drug chidamide (Tucidinostat) in 15 people aged 60 or older with intermediate-to-high-risk myelodysplastic syndromes (MDS), a bone marrow disorder that can lead to leukemia. Participants take chidamide orally twice a week for up to 3 months. The study…
Phase: PHASE2 • Sponsor: Zhongshan Hospital (Xiamen), Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for tough leukemia? drug duo targets TP53 mutations
Disease control Not yet recruitingThis early-phase study tests a new drug (ATRN-119) combined with a standard chemotherapy (decitabine) in 27 adults with acute myeloid leukemia or high-risk myelodysplastic syndrome that has a TP53 gene change. The main goals are to find a safe dose and see if the combo can shrink…
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New pill takes on tough blood cancers in first human trial
Disease control Not yet recruitingThis early-stage study tests a new tablet, FXS0683, in 228 adults with blood cancers like lymphoma or leukemia that returned or didn't respond to standard therapy. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will be clo…
Phase: PHASE1 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for young leukemia patients: experimental drug combo targets resistant cancer
Disease control Not yet recruitingThis study tests a new drug called asciminib, given with chemotherapy and later with another drug (blinatumomab), in children, teens, and young adults up to age 30 who have a type of leukemia (Ph+ or Ph-like ALL) that has come back or not responded to treatment. The goal is to fi…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New Bacteria-Based therapy tested for leukemia relapse prevention
Disease control Not yet recruitingThis early-stage trial tests a new treatment called QUAIL-100, made from a live weakened bacteria, in children and young adults with high-risk leukemia or myelodysplastic syndrome who have already had a stem cell transplant. The main goal is to check safety and side effects. Only…
Phase: PHASE1 • Sponsor: Laguna Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo therapy aims to boost red blood cells in bone marrow disease
Disease control Not yet recruitingThis study tests whether adding epoetin alfa or emavusertib to luspatercept helps people with low-risk myelodysplastic syndrome (MDS) and anemia. MDS is a bone marrow disorder that leads to low blood counts. The goal is to see if these combinations improve red blood cell producti…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for tough blood cancer: experimental drug targets resistant MDS
Disease control Not yet recruitingThis study tests a new drug called BL-M11D1 in 92 adults with a type of blood cancer called myelodysplastic syndromes (MDS) that has returned or not improved with standard treatments. The goal is to find the best dose and see if the drug is safe and can shrink or eliminate cancer…
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New radiation method may make stem cell transplants safer for older leukemia patients
Disease control Not yet recruitingThis study tests a targeted radiation technique (TMLI) combined with two chemotherapy drugs before a stem cell transplant in people aged 50 and older with acute myeloid leukemia or myelodysplastic syndrome that has not responded to treatment or has returned. The goal is to see if…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could a common drug curb polyps in teens with rare genetic condition?
Disease control Not yet recruitingThis study tests two low doses of rapamycin, a drug usually used to prevent organ rejection, in 25 teenagers (ages 12-17) with familial adenomatous polyposis (FAP), a genetic condition that causes many colon polyps and raises cancer risk. The main goal is to see if the drug is sa…
Phase: PHASE2 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Promising combo targets tough leukemia
Disease control Not yet recruitingThis study tests a new way to treat a fast-growing blood cancer called BCR-ABL positive B-cell acute lymphoblastic leukemia. About 80 adults will receive two drugs: ponatinib pills and blinatumomab injections under the skin. The goal is to see if this combination can control the …
Phase: PHASE2 • Sponsor: University of Alberta • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Leukemia combo shot and pill shows promise in early trial
Disease control Not yet recruitingThis Phase 2 trial tests a combination of two drugs—blinatumomab (given as a shot under the skin) and olverembatinib (a pill)—in 60 adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). The goal is to see if this combo can control the disease safely. Pa…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug cocktail aims to stop leukemia relapse after transplant
Disease control Not yet recruitingThis study tests whether adding SHR2554 and azacitidine to standard chemotherapy before a stem cell transplant can lower the chance of cancer returning in people aged 15-60 with high-risk or relapsed leukemia or myelodysplastic syndromes. Half the participants will get the new dr…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Can patients stop Anti-Rejection drugs sooner after transplant?
Disease control Not yet recruitingThis study tests whether patients can safely stop the drug tacrolimus earlier than usual after a stem cell transplant. Tacrolimus is given to prevent graft-versus-host disease (GVHD), but newer methods have lowered GVHD risk. The trial will enroll 50 people with blood cancers and…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New combo aims to cut infections in bone marrow cancer
Disease control Not yet recruitingThis study tests a new oral liquid drug, BLEX 404, combined with a standard chemotherapy (azacitidine) for people with certain types of bone marrow cancers (MDS and CMML). The goal is to find a safe dose and see if it can reduce serious infections. About 52 adults who have not be…
Phase: PHASE2 • Sponsor: BioLite, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug cocktail aims to beat back aggressive throat cancer
Disease control Not yet recruitingThis Phase 3 trial tests whether adding a targeted drug (Becotatug Vedotin) to standard immunotherapy and chemo-radiation can improve outcomes for people with high-risk nasopharyngeal cancer. About 514 participants will be randomly assigned to receive either the new combo or stan…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo aims to tackle tough brain tumors in NF1 patients
Disease control Not yet recruitingThis phase 2 trial tests the drug mirdametinib, alone or with radiation, in people with NF1-related high-grade gliomas (aggressive brain tumors). It includes three groups: those with recurrent sporadic glioblastoma, newly diagnosed NF1-associated glioblastoma, and other NF1-relat…
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Could a common diabetes pill treat anemia in MDS patients?
Disease control Not yet recruitingThis study tests whether dapagliflozin, a drug used for diabetes, can help treat anemia in people with lower-risk myelodysplastic syndromes (MDS). Anemia is a common problem in MDS, causing fatigue and often requiring blood transfusions. The trial will give 37 participants dapagl…
Phase: PHASE2 • Sponsor: Seug yun Yoon, MD • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for Hard-to-Treat leukemia? early trial combines three drugs
Disease control Not yet recruitingThis early-phase trial is testing a new drug called axatilimab added to two standard chemotherapy drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has a TP53 mutation or deletion. The study aims to find the safest dose of axatilimab and see how …
Phase: PHASE1 • Sponsor: Northside Hospital, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can Exercise-Powered immune cells stop leukemia from coming back?
Disease control Not yet recruitingThis early-phase trial tests a new approach using donor immune cells that have been mobilized through exercise to prevent or treat leukemia relapse after a stem cell transplant. The study will enroll 94 people with various blood cancers. Some will receive the exercise-mobilized c…
Phase: PHASE1 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Could one antibiotic replace two for chemo fevers? major trial launches
Disease control Not yet recruitingThis study compares a single antibiotic (amoxicillin-clavulanate) against the standard two-drug combination (amoxicillin-clavulanate plus ciprofloxacin) for treating fever caused by chemotherapy in adults with certain blood cancers. The goal is to see if the simpler treatment wor…
Phase: PHASE3 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug cocktail aims to shrink NF1 tumors
Disease control Not yet recruitingThis early-stage trial tests whether two cancer drugs, cabozantinib and selumetinib, can safely shrink plexiform neurofibromas in people aged 16 and older with neurofibromatosis type 1 (NF1). About 30 participants will receive the combination daily. The study first finds the safe…
Phase: PHASE1 • Sponsor: Girish Dhall, MD • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope: interferon drug may stop deadly blood cancers from coming back after transplant
Disease control Not yet recruitingThis study tests whether the drug interferon-α can lower the chance of cancer returning in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have a TP53 gene mutation. Participants must have had a stem cell transplant and show no signs of cancer two m…
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo aims to clear leukemia before transplant
Disease control Not yet recruitingThis phase 2 trial tests whether combining olverembatinib (a targeted pill) with inotuzumab ozogamicin (an antibody-drug conjugate) can clear remaining leukemia cells in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who still have detectable …
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Could immunotherapy spare some colon cancer patients from surgery?
Disease control Not yet recruitingThis study tests giving an immunotherapy drug (pembrolizumab) before surgery to people with a specific type of colon cancer (dMMR). The goal is to see if the drug can shrink or eliminate the tumor so some patients may avoid surgery and instead be closely monitored. About 152 adul…
Phase: PHASE2 • Sponsor: Ismail Gögenur • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug cocktail takes on rare nerve tumors
Disease control Not yet recruitingThis early-phase trial tests a combination of three drugs—selumetinib, ZEN-3694, and durvalumab—in people with advanced sarcomas, including malignant peripheral nerve sheath tumors (MPNST) linked to NF1. The study first checks safety and dosing, then looks at whether the treatmen…
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New combo therapy aims to shrink Hard-to-Treat colorectal tumors before surgery
Disease control Not yet recruitingThis study tests whether giving immunotherapy drugs (nivolumab with or without ipilimumab) or immunotherapy plus radiotherapy before surgery can improve outcomes for people with a specific genetic type of colorectal cancer called MSI-H/dMMR. About 114 participants will be randoml…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Sound waves and immunotherapy join forces against deadly brain tumor
Disease control Not yet recruitingThis early-phase study tests whether combining focused ultrasound with the immunotherapy drug pembrolizumab is safe and feasible for people with recurrent glioblastoma, a severe brain cancer. Only 8 participants with a specific genetic feature (mismatch repair deficiency) will be…
Phase: PHASE1 • Sponsor: Jennifer Leddon • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New cocktail of drugs aims to stop High-Risk throat cancer in its tracks
Disease control Not yet recruitingThis Phase 3 trial will test whether adding anlotinib (a drug that cuts off tumor blood supply) to standard immunotherapy and chemotherapy with radiation can improve outcomes for 412 people with high-risk nasopharyngeal cancer. Participants will receive either the new combo or st…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug aims to stop deadly transplant complication
Disease control Not yet recruitingThis study tests a drug called ivarmacitinib to prevent acute graft-versus-host disease (aGVHD) in 32 people with blood cancers receiving a half-matched stem cell transplant. The goal is to see if the drug can lower the chance of severe GVHD and improve survival without long-term…
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Could a drug combo replace the knife for some endometrial cancers?
Disease control Not yet recruitingThis study tests two immunotherapy drugs (iparomlimab and tuvonralimab) in 30 women with a specific type of endometrial cancer that is mismatch repair-deficient. The goal is to see if the treatment can make the cancer disappear or shrink enough to avoid surgery. Participants must…
Phase: PHASE2 • Sponsor: Women's Hospital School Of Medicine Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy aims to wipe out stomach cancer before surgery
Disease control Not yet recruitingThis phase 2 trial tests two different drug combinations given before surgery for people with a specific type of stomach cancer (dMMR/MSI-H). Participants will receive the immunotherapy drug adebrelimab plus either chemotherapy or another immunotherapy drug (SHR-8068). The goal i…
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could less immunotherapy be just as good for advanced nose cancer?
Disease control Not yet recruitingThis phase 3 trial will test whether a shorter course of the immunotherapy drug tislelizumab, combined with chemotherapy and radiation, works as well as a longer course for people with advanced nasopharyngeal cancer. About 418 participants will be randomly assigned to receive eit…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New pill aims to shrink tumors in rare nerve disorder
Disease control Not yet recruitingThis early-phase trial tests an oral drug called Trineumin (PRG-N-01) in 25 adults with neurofibromatosis type II (NF2), a genetic condition that causes non-cancerous tumors on nerves. The study has two parts: first finding a safe dose, then checking if that dose can shrink tumor…
Phase: PHASE1, PHASE2 • Sponsor: PRG Science & Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for kids: drug combo aims to stop transplant complications
Disease control Not yet recruitingThis early-phase study tests whether adding an experimental drug (VIC-1911) to standard medications can prevent graft-versus-host disease (GVHD) in children aged 8-18 who receive a stem cell transplant from a half-matched donor. GVHD occurs when donor cells attack the child's bod…
Phase: PHASE1 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Real-World data sought on Ponatinib's impact against rare leukemia
Disease control Not yet recruitingThis study reviews medical records of 103 adults with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who received ponatinib as their first treatment in regular care. Researchers want to see how many patients achieve a complete molecular response (undetectable leukem…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New study aims to outsmart relapse in aggressive blood cancers after transplant
Disease control Not yet recruitingThis study compares two ways of giving donor immune cells (DLI) after a stem cell transplant to prevent cancer from coming back in people with relapsed or hard-to-treat acute myeloid leukemia or myelodysplastic syndromes. One approach gives the cells early as a preventive measure…
Phase: NA • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug aims to cut transfusions for MDS patients
Disease control Not yet recruitingThis study tests a drug called TAK-226 (Elritercept) in 27 Japanese adults with lower-risk myelodysplastic syndromes (MDS) who need regular blood transfusions. The goal is to see if the drug can help them go without transfusions for at least 8 weeks. Participants will receive inj…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for stomach cancer: immunotherapy combo targets resistant tumors
Disease control Not yet recruitingThis phase 2 trial will test a combination of immunotherapy drugs and chemotherapy given before surgery for people with a specific genetic subtype of stomach cancer (dMMR/MSI-H). The study aims to see how well this approach clears the tumor and to understand why some patients do …
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New pill aims to tame seizures in rare brain disorders
Disease control Not yet recruitingThis early-stage trial tests an oral drug called SVG103 (Paxalisib) in 15 adults with rare brain conditions (FCD-II, TSC, or HME) that cause seizures. The main goal is to check safety and side effects, while also seeing if it reduces seizure frequency. Participants take the drug …
Phase: PHASE1, PHASE2 • Sponsor: Sovargen • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New hope for Cushing's patients with high blood pressure
Disease control Not yet recruitingThis study tests a drug called osilodrostat in 63 adults with Cushing's syndrome and high blood pressure. The goal is to see if it can safely lower blood pressure by reducing cortisol levels. Participants will take the drug or a placebo for 30 weeks, with doses adjusted based on …
Phase: PHASE4 • Sponsor: RECORDATI GROUP • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug duo aims to shrink throat tumors before standard care
Disease control Not yet recruitingThis study tests whether giving two drugs (pembrolizumab and MRG-003) before standard chemoradiation can shrink tumors in people with advanced nasopharyngeal cancer linked to Epstein-Barr virus. About 35 adults with stage III-IVa disease will receive 3 cycles of the drug combo, t…
Phase: PHASE2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New pill hopes to fight multiple cancers when other treatments fail
Disease control Not yet recruitingThis early-stage trial tests an experimental drug called ACC-1898, taken as a daily pill, in adults with advanced solid tumors (like liver, kidney, or stomach cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see how the body handl…
Phase: PHASE1 • Sponsor: AccSalus Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Real-World check: is talzenna safe for advanced breast cancer?
Disease control Not yet recruitingThis study will track 600 people in Korea with advanced breast cancer who are already being prescribed Talzenna. Researchers will watch for side effects and see how well the drug works in everyday medical practice, not in a strict research setting. The goal is to confirm the drug…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New pill shows promise in brain cancer fight
Disease control Not yet recruitingThis study tests whether adding NG101m capsules to standard chemoradiation helps people with newly diagnosed glioblastoma live longer. About 52 adults will receive NG101m alongside usual care. The goal is to see if the combination is safe and improves 2-year survival.
Phase: PHASE1, PHASE2 • Sponsor: NeuGATE Theranostics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New transplant prep aims to boost survival in leukemia patients
Disease control Not yet recruitingThis phase 2 trial tests whether adding venetoclax to standard chemotherapy before a stem cell transplant can improve survival for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The study will enroll 27 adults aged 18 to 75. The main goal is…
Phase: PHASE2 • Sponsor: University Hospital Tuebingen • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Cord blood infusion may speed bone marrow recovery in older cancer patients
Disease control Not yet recruitingThis study tests whether infusing umbilical cord blood can safely help elderly patients (ages 60-80) with MDS or AML recover from bone marrow suppression caused by chemotherapy. The treatment aims to improve blood cell counts and reduce complications like bleeding and infection. …
Phase: NA • Sponsor: Shandong Qilu Stem Cells Engineering Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Cancer drug RVU120 gets extended trial for ongoing patients
Disease control Not yet recruitingThis study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…
Phase: PHASE2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New trial aims to find safer chemo for stem cell transplants in leukemia patients
Disease control Not yet recruitingThis study tests two chemotherapy drugs, treosulfan and melphalan, given before a stem cell transplant in 220 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to see which drug works better at helping patients survive longer with fewer side …
Phase: PHASE2 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Jun 26, 2026 12:47 UTC
-
New imaging agent could improve detection of rare cancers
Diagnosis Not yet recruitingThis study will compare a new radioactive tracer, 18F-AmBF3TATE, to the standard tracer 68Ga-DOTATATE for PET scans in people with neuroendocrine tumors. The goal is to see if the new tracer is as good or better at finding tumors. About 51 participants will receive both tracers a…
Sponsor: British Columbia Cancer Agency • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
Could a pill camera replace the colonoscopy for lynch syndrome patients?
Diagnosis Not yet recruitingThis study tests whether a swallowable capsule camera (colon capsule endoscopy) can effectively screen for colorectal cancer in people with Lynch syndrome, a genetic condition that greatly increases cancer risk. Researchers will compare the capsule's ability to find polyps and ot…
Sponsor: Region Skane • Aim: Diagnosis
Last updated Jun 27, 2026 12:25 UTC
-
Liquid biopsies may let lynch syndrome patients skip half their colonoscopies
Diagnosis Not yet recruitingThis study tests whether annual liquid biopsies (from blood, urine, stool, and vaginal swabs) can safely replace colonoscopies every 18 months for people with Lynch syndrome. 2,000 participants will be split into two groups: one gets standard care (colonoscopy every 18 months), t…
Phase: NA • Sponsor: UNICANCER • Aim: Diagnosis
Last updated Jun 27, 2026 08:13 UTC
-
New DNA sequencer could make genetic testing cheaper and faster
Diagnosis Not yet recruitingThis study compares a new DNA sequencing platform (MGI) against the current standard (Illumina) for diagnosing hereditary cancers like breast and ovarian cancer, Lynch syndrome, and intestinal polyposis. Researchers will analyze 248 patient samples using both platforms to see if …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Jun 26, 2026 14:56 UTC
-
Personalized vaccine aims to stop lynch syndrome cancers before they start
Prevention Not yet recruitingThis phase III trial tests whether a vaccine made from a person's own immune cells can prevent cancer in 372 adults with Lynch syndrome, a genetic condition that raises cancer risk. Participants receive either the vaccine or a placebo and are monitored for tumor development. The …
Phase: PHASE3 • Sponsor: Radboud University Medical Center • Aim: Prevention
Last updated Jun 27, 2026 12:37 UTC
-
Could a vaccine stop cancer before it starts in lynch syndrome?
Prevention Not yet recruitingThis early-phase trial tests a personalized vaccine made from a person's own immune cells (dendritic cells) loaded with cancer-specific markers. The goal is to train the immune system to recognize and destroy precancerous cells in people with Lynch syndrome, who have a high risk …
Phase: PHASE1, PHASE2 • Sponsor: Radboud University Medical Center • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Could a 'Baby Dose' of hormone pills prevent breast cancer?
Prevention Not yet recruitingThis study tests whether low doses of two hormone-blocking drugs, exemestane and tamoxifen, can help prevent breast cancer in postmenopausal women at high risk. About 140 women will take one of the two drugs for a year, and researchers will measure side effects and quality of lif…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Prevention
Last updated Jun 27, 2026 12:01 UTC
-
Healing harmonies: music therapy aims to ease stem cell transplant recovery
Symptom relief Not yet recruitingThis study tests an online music therapy program that combines mindfulness and music to help people recovering from stem cell transplants for blood cancers. Researchers want to see if it can improve quality of life, reduce pain, fatigue, anxiety, and depression, and possibly spee…
Phase: NA • Sponsor: University of Miami • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Robot-Assisted mastectomy: could it mean less pain and faster healing?
Symptom relief Not yet recruitingThis study compares two types of nipple-sparing mastectomy: one done with a robotic arm through a small side incision, and the standard open surgery. Researchers want to see if the robotic method improves women's satisfaction, body image, and recovery over 12 months. The trial wi…
Phase: NA • Sponsor: Beaumont Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
Could you help scientists unlock genetic cancer secrets?
Knowledge-focused Not yet recruitingThis study screens up to 1,000 people with personal or family histories of certain cancers to see if they qualify for ongoing genetics research at the National Cancer Institute. Participants fill out a 15-20 minute online survey about their health and family history. No treatment…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Can a simple social check improve leukemia care?
Knowledge-focused Not yet recruitingThis study looks at whether screening adults with leukemia for social needs (like housing or food) and offering early social work help is practical and helpful. About 80 newly diagnosed patients will either get the screening and consultation or usual care. The goal is to see if t…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Scientists investigate how immune cells fight leukemia
Knowledge-focused Not yet recruitingThis study will collect blood and bone marrow samples from 55 adults with acute leukemia or myelodysplastic syndrome. Researchers want to understand how natural killer (NK) cells interact with cancer cells over time. The goal is to identify genetic markers and immune patterns tha…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New online toolkit aims to boost cancer screening in lynch syndrome families
Knowledge-focused Not yet recruitingThis study tests an online tool called 'Let's Talk' designed to help people with Lynch syndrome encourage their relatives to get screened for the condition. Lynch syndrome is a genetic disorder that raises cancer risk, and only about half of close relatives currently get tested. …
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Could cousins be as good as siblings for stem cell donation?
Knowledge-focused Not yet recruitingThis study looks at whether using a cousin as a stem cell donor works as well as using a sibling for people with blood cancers. Researchers will compare survival, relapse, and side effects like graft-versus-host disease in patients who received a transplant from either a cousin o…
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Stomach cancer study may spare some patients unnecessary surgery
Knowledge-focused Not yet recruitingThis study looks at whether a tumor's DNA repair status (MMR) changes how well the presence of cancer cells in lymph vessels predicts spread to lymph nodes in stomach cancer. Researchers will review medical records of 3,000 patients who had surgery. The goal is to improve risk as…
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a digital guide boost genetic testing in prostate cancer survivors?
Knowledge-focused Not yet recruitingThis study looks at the best way to help prostate cancer survivors learn about and get genetic testing for inherited cancer risks. About 500 participants will be randomly assigned to a digital guide, a printed guide, or standard care. Researchers will track who requests testing a…
Phase: NA • Sponsor: Georgetown University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
New blood test may predict cancer relapse after transplant
Knowledge-focused Not yet recruitingThis study is testing a new blood test called AlloHeme that looks for tiny traces of a patient's own cells after a stem cell transplant. The goal is to see if the test can predict whether leukemia or MDS will come back before it happens. About 400 adults who have had or will have…
Sponsor: CareDx • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Could lynch syndrome raise your risk of gum disease?
Knowledge-focused Not yet recruitingThis study will check if people with Lynch syndrome, a genetic condition that raises cancer risk, have more gum disease than the general population. Researchers will look at dental records from 25 adults with Lynch syndrome. The goal is to see if gum disease is a hidden health is…
Sponsor: Rotundo Roberto • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New online program aims to boost genetic cancer testing in african american families
Knowledge-focused Not yet recruitingThis study tests a web-based program called Kindred that helps African American families understand their genetic cancer risk and talk about testing. About 150 people will use the tool to see if it improves knowledge and testing rates. The goal is to make genetic information more…
Phase: NA • Sponsor: University of Michigan Rogel Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
New online tool aims to help families uncover hidden cancer risks
Knowledge-focused Not yet recruitingThis study tests whether a new online program can help families understand their inherited cancer risk and encourage relatives to get low-cost genetic testing. Researchers will enroll 400 adults who carry a cancer-related gene change and their family members. The goal is to see i…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Can a simple walk test spot motor trouble in kids with NF1?
Knowledge-focused Not yet recruitingThis study looks at how young children with neurofibromatosis type 1 (NF1) walk, to see if simple walking tests can help doctors spot and predict movement problems early. Researchers will measure walking speed and other skills in 56 children under 6 years old. The goal is to crea…
Sponsor: NYU Langone Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
New program aims to keep High-Risk cancer gene carriers on track with screenings
Knowledge-focused Not yet recruitingThis study tests a program to help people with inherited cancer gene mutations (like BRCA or Lynch syndrome) stick to recommended cancer screening schedules. Researchers will interview 80 female participants and provide standard care to see if this approach improves adherence and…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Could a simple skin test replace bone marrow biopsies?
Knowledge-focused Not yet recruitingThis study explores whether a non-invasive, painless skin measurement called electrical bioimpedance can help monitor acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). About 25 adults who are already scheduled for a bone marrow biopsy will also receive this skin te…
Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
50,000 samples to unlock secrets of hereditary tumors
Knowledge-focused Not yet recruitingThis study will collect blood and tumor tissue from up to 50,000 adults with hereditary or genetic-linked cancers. Researchers will use these samples to create lab-grown tumor models, like mini-tumors, to study how these cancers work and test new treatments. The goal is to better…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Not yet recruitingThis study is a registry that will collect medical information and blood samples from 500 adults with myelodysplastic syndromes (MDS) and related conditions. The goal is to learn more about how these diseases develop and progress over time. Participants will not receive any exper…
Sponsor: Technische Universität Dresden • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Scientists investigate hidden genetic patterns in rare childhood disorders
Knowledge-focused Not yet recruitingThis study aims to better understand a condition called multilocus imprinting disorder (MLID), where multiple genes are affected by abnormal chemical marks. Researchers will test a new technique to detect these marks in 96 people, including those with known imprinting disorders a…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Massive study to uncover hidden link between blood mutations and immune disorders
Knowledge-focused Not yet recruitingThis study will follow 5,000 adults with immune system problems to see if certain blood cell mutations (called clonal hematopoiesis) are linked to their condition. Researchers will track new cases of immune-related diseases over time. No treatments or drugs are tested—this is pur…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Could a protein on blood cancer cells lead to a new treatment?
Knowledge-focused Not yet recruitingThis study looks at a protein called IL-1RAP found on the surface of certain blood cancer cells in myelodysplastic syndromes (MDS). Researchers want to see if this protein can be targeted by a special immune therapy called CAR-T cells. They will collect bone marrow and blood samp…
Phase: NA • Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
New study aims to predict deadly infections in blood cancer patients
Knowledge-focused Not yet recruitingThis study looks at blood cancer patients who carry drug-resistant bacteria in their gut. Researchers want to find out who is most likely to get a serious infection from these bacteria. They will collect rectal swabs and track patients for 90 days to build a prediction tool. The …
Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
New registry to map MDS in asia: no treatment, just data
Knowledge-focused Not yet recruitingThis study is a registry that will collect information from about 500 adults in Asia who have been diagnosed with myelodysplastic syndromes (MDS). Researchers will look at patient details like age, sex, medical history, lab results, and treatments received. The goal is to better …
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
CAR-T therapy survivors monitored for Long-Term safety and survival
Knowledge-focused Not yet recruitingThis study follows up to 49 people with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who previously received ARD103 CAR-T cell therapy in an earlier trial. Researchers will track side effects, overall survival, and how long any response lasts. The goal …
Sponsor: ARCE Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
Simple Pre-Surgery steps could boost stoma Patients' quality of life
Knowledge-focused Not yet recruitingThis study will follow 100 people who need a stoma (an opening in the belly to pass stool) after surgery. Some will have their stoma site marked and get education before surgery, while others will not. The goal is to see if these steps improve quality of life and reduce problems …
Phase: NA • Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
New study aims to decode glioblastoma through brain scans and blood markers
Knowledge-focused Not yet recruitingThis study will include 30 people newly diagnosed with glioblastoma, the most common and aggressive brain tumor. Researchers will use a special MRI technique called magnetic resonance spectroscopy (MRS) to measure chemicals in the tumor, and also test blood for certain markers. T…
Phase: NA • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Blood markers may forecast MDS outcomes
Knowledge-focused Not yet recruitingThis study will look at 100 adults with myelodysplastic syndromes (MDS) to see if certain blood test results can help predict how the disease will progress. Researchers will check levels of hemoglobin, albumin, lymphocytes, platelets, and other factors. The goal is to better unde…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Does an enlarged spleen change the outlook for low platelet patients?
Knowledge-focused Not yet recruitingThis study will look at 100 adults with low platelet counts to see how many have an enlarged spleen and whether that affects their symptoms, complications, or response to treatment. The goal is to better understand the role of the spleen in these blood disorders. No new treatment…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:59 UTC